FDA Oncology Announcements

HIF-2a inhibitor × Endocrine × Clear all

2 Announcements

FDA approves belzutifan for pheochromocytoma or paraganglioma

Trial: MK-6482-015
Drug: Welireg (belzutifan) · HIF-2a inhibitor
Conditions: CNSEndocrine

FDA approves belzutifan for cancers associated with von Hippel-Lindau disease

Trial: MK-6482-004
Drug: Welireg (belzutifan) · HIF-2a inhibitor
Conditions: EndocrineGastrointestinalGenitourinaryNET